78 related articles for article (PubMed ID: 23902290)
21. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
[TBL] [Abstract][Full Text] [Related]
22. Proteomic identification of overexpressed PRDX 1 and its clinical implications in ovarian carcinoma.
Chung KH; Lee DH; Kim Y; Kim TH; Huh JH; Chung SG; Lee S; Lee C; Ko JJ; An HJ
J Proteome Res; 2010 Jan; 9(1):451-7. PubMed ID: 19902980
[TBL] [Abstract][Full Text] [Related]
23. LC-MS/MS analysis of ovarian cancer metastasis-related proteins using a nude mouse model: 14-3-3 zeta as a candidate biomarker.
He Y; Wu X; Liu X; Yan G; Xu C
J Proteome Res; 2010 Dec; 9(12):6180-90. PubMed ID: 21028892
[TBL] [Abstract][Full Text] [Related]
24. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
[TBL] [Abstract][Full Text] [Related]
25. Identification of apolipoprotein A1 in the human embryonic secretome.
Mains LM; Christenson L; Yang B; Sparks AE; Mathur S; Van Voorhis BJ
Fertil Steril; 2011 Aug; 96(2):422-427.e2. PubMed ID: 21676393
[TBL] [Abstract][Full Text] [Related]
26. [Early proteomics in ovarian cancer: myth or reality?].
Makarov OV; Govorun VM; Taranets IN; Goufman EI; Gritsaĭ AN; Archakov AI
Biomed Khim; 2003; 49(1):2-7. PubMed ID: 14569865
[TBL] [Abstract][Full Text] [Related]
27. Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer.
Matei D; Emerson RE; Lai YC; Baldridge LA; Rao J; Yiannoutsos C; Donner DD
Oncogene; 2006 Mar; 25(14):2060-9. PubMed ID: 16331269
[TBL] [Abstract][Full Text] [Related]
28. [Nucleic factor in the ascitic fluid in human ovarian tumors].
Zelenkova NK; Belokhvostov AS; Lipova VA; Aĭnbinder NM
Vopr Onkol; 1980; 26(8):45-8. PubMed ID: 7415050
[TBL] [Abstract][Full Text] [Related]
29. Characterization of serum biomarkers for detection of early stage ovarian cancer.
Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
31. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions.
Davidson B; Berner A; Nesland JM; Risberg B; Kristensen GB; Tropé CG; Bryne M
Hum Pathol; 2000 Sep; 31(9):1081-7. PubMed ID: 11014575
[TBL] [Abstract][Full Text] [Related]
32. [Comparative proteomics analysis of differentially expressed metastasis-associated proteins in human ovarian cancer cell lines].
Su D; Xu SH; Gu LH
Zhonghua Fu Chan Ke Za Zhi; 2005 Sep; 40(9):619-22. PubMed ID: 16202319
[TBL] [Abstract][Full Text] [Related]
33. Angiogenic protein expression in advanced epithelial ovarian cancer.
Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
[TBL] [Abstract][Full Text] [Related]
34. Integrative proteomic analysis of serum and peritoneal fluids helps identify proteins that are up-regulated in serum of women with ovarian cancer.
Amon LM; Law W; Fitzgibbon MP; Gross JA; O'Briant K; Peterson A; Drescher C; Martin DB; McIntosh M
PLoS One; 2010 Jun; 5(6):e11137. PubMed ID: 20559444
[TBL] [Abstract][Full Text] [Related]
35. Bubble-driven mixer integrated with a microfluidic bead-based ELISA for rapid bladder cancer biomarker detection.
Lin YH; Wang CC; Lei KF
Biomed Microdevices; 2014 Apr; 16(2):199-207. PubMed ID: 24141738
[TBL] [Abstract][Full Text] [Related]
36. Haptoglobin and CCR2 receptor expression in ovarian cancer cells that were exposed to ascitic fluid: exploring a new role of haptoglobin in the tumoral microenvironment.
Garibay-Cerdenares OL; Hernández-Ramírez VI; Osorio-Trujillo JC; Gallardo-Rincón D; Talamás-Rohana P
Cell Adh Migr; 2015; 9(5):394-405. PubMed ID: 26211665
[TBL] [Abstract][Full Text] [Related]
37. Peritoneal biomarkers in the early detection of ovarian cancer.
Galea M; Gauci G; Calleja-Agius J; Schembri-Wismayer P
Minerva Ginecol; 2017 Feb; 69(1):84-99. PubMed ID: 27284942
[TBL] [Abstract][Full Text] [Related]
38. [Interleukin 6 (IL-6)--a biological marker in patients with ovarian cancer?].
Schröder W; Ruppert C; Bender HG
Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():200-1. PubMed ID: 8118269
[No Abstract] [Full Text] [Related]
39. Is ascitic fluid interleukin-12 an independent prognostic factor in ovarian cancer? The necessity of correction milligram P values for multiple comparisons.
Kudelka AP; Lenzi R; Atkinson EN; Levy LB; Freedman RS
J Clin Oncol; 1998 Sep; 16(9):3208-9. PubMed ID: 9738599
[No Abstract] [Full Text] [Related]
40. Fibrinolysis in ascitic fluid: isolation and characterization of fibrin derivatives, their interaction with albumin.
Wilhelm O; Hafter R; Graeff H
Thromb Res; 1987 Sep; 47(6):673-81. PubMed ID: 3686482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
